Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine extended release liposome injection
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Infiltration, Perineural
01
Overview
Bupivacaine extended release liposome injection is a novel formulation of the amide-type local anesthetic bupivacaine, encapsulated in multivesicular liposomes (DepoFoam technology) to provide prolonged postsurgical analgesia. The drug is designed for single-dose infiltration or perineural use and achieves long-acting pain relief by gradually releasing bupivacaine at the site of administration over up to 72 hours. This reduces opioid requirements and improves patient satisfaction after surgery compared with placebo or standard formulations. It is not bioequivalent to other forms of bupivacaine and should not be substituted on a milligram-to-milligram basis[2][3][5][8].
- Brand names
- EXPAREL
- Other names
- bupivacaine liposome injectable suspensionliposomal bupivacainebupivacaine extended-release liposome injection
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)
Beyond the preview
Go deeper on bupivacaine extended release liposome injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine extended release liposome injection.